Losartan/thioctic acid

Drug Profile

Losartan/thioctic acid

Alternative Names: Alpha lipoic acid/losartan; INV-144; Losartan/alpha lipoic acid; Thioctic acid/losartan

Latest Information Update: 07 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator InVasc Therapeutics
  • Class Antihypertensives; Biphenyl compounds; Imidazoles; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Antioxidants; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Diabetic nephropathies

Most Recent Events

  • 07 Sep 2015 No recent reports on development identified - Phase-II for Diabetic nephropathies in USA (PO)
  • 01 Jul 2012 InVasc Therapeutics completes a phase I/II trial in Diabetic nephropathies in USA (NCT01398423)
  • 02 Apr 2012 InVasc Therapeutics completes enrolment in its phase II trial for Diabetic nephropathies in USA (NCT01398423)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top